1	Please	please	UH	_	2	intj	2:AM-DIS
2	enter	enter	VB	pb=enter.01	0	root	_
3	your	your	PRP$	_	4	poss	_
4	username	username	NN	_	2	dobj	2:A1=LOC
5	or	or	CC	_	4	cc	_
6	email	email	NN	_	7	nn	_
7	address	address	NN	_	4	conj	8:A1
8	provided	provided	VBN	pb=provide.01	7	partmod	_
9	during	during	IN	_	8	prep	8:AM-TMP
10	registration	registration	NN	_	9	pobj	_
11	.	.	.	_	2	punct	_

1	If	if	IN	_	7	mark	_
2	your	your	PRP$	_	3	poss	_
3	username	username	NN	_	7	nsubj	7:A1=PAG
4	or	or	CC	_	3	cc	_
5	email	email	NN	_	6	nn	_
6	address	address	NN	_	3	conj	_
7	exist	exist	VBP	p2=VB|pb=exist.01	14	advcl	14:AM-ADV
8	in	in	IN	_	7	prep	7:AM-LOC
9	our	our	PRP$	_	10	poss	_
10	database	database	NN	_	8	pobj	_
11	,	,	,	_	14	punct	_
12	you	you	PRP	_	14	nsubj	14:A0=PAG
13	will	will	MD	_	14	aux	14:AM-MOD
14	receive	receive	VB	pb=receive.01	0	root	_
15	instructions	instruction	NNS	_	14	dobj	14:A1=PPT
16	how	how	WRB	_	18	advmod	18:R-AM-MNR
17	to	to	TO	_	18	aux	_
18	reset	reset	VB	pb=reset.01	15	infmod	_
19	your	your	PRP$	_	20	poss	_
20	password	password	NN	_	18	dobj	18:A1=PPT
21	.	.	.	_	14	punct	_

1	Researchers	researcher	NNS	_	6	nsubj	6:A0=PAG
2	from	from	IN	_	1	prep	_
3	UC	uc	NNP	_	5	nn	_
4	San	san	NNP	_	5	nn	_
5	Francisco	francisco	NNP	_	2	pobj	_
6	played	play	VBD	pb=play.02	0	root	_
7	major	major	JJ	_	8	amod	_
8	roles	role	NNS	_	6	dobj	6:A1=PPT
9	in	in	IN	_	6	prep	6:AM-LOC
10	five	#crd#	CD	_	13	num	_
11	significant	significant	JJ	_	13	amod	_
12	multicenter	multicenter	JJ	p2=NN	13	amod	_
13	studies	study	NNS	_	9	pobj	17:A1=PRD
14	of	of	IN	_	13	prep	_
15	lung	lung	NN	p2=JJ	16	nn	_
16	disease	disease	NN	_	14	pobj	_
17	published	publish	VBN	pb=publish.01	13	partmod	_
18	May	may	NNP	_	17	npadvmod	17:AM-TMP
19	18	0	CD	_	18	num	_
20	,	,	,	_	18	punct	_
21	2014	0	CD	_	18	num	_
22	in	in	IN	p2=CC	17	prep	17:AM-LOC
23	The	the	DT	_	26	det	_
24	New	new	NNP	_	25	nn	_
25	England	england	NNP	_	26	nn	_
26	Journal	journal	NNP	_	22	pobj	_
27	of	of	IN	_	26	prep	_
28	Medicine	medicine	NNP	_	27	pobj	_
29	(	(	-LRB-	_	26	punct	_
30	NEJM	nejm	NNP	_	26	appos	_
31	)	)	-RRB-	_	26	punct	_
32	.	.	.	_	6	punct	_

1	In	in	IN	_	11	prep	11:AM-LOC
2	one	#crd#	CD	_	3	num	_
3	set	set	NN	_	1	pobj	_
4	of	of	IN	_	3	prep	_
5	trials	trial	NNS	_	4	pobj	_
6	,	,	,	_	11	punct	_
7	three	#crd#	CD	_	9	num	_
8	different	different	JJ	_	9	amod	_
9	drugs	drug	NNS	_	11	nsubjpass	11:A1=LOC
10	were	be	VBD	_	11	auxpass	_
11	tested	test	VBN	pb=test.01	0	root	_
12	in	in	IN	_	11	prep	11:AM-LOC
13	separate	separate	JJ	_	14	amod	_
14	studies	study	NNS	_	12	pobj	_
15	for	for	IN	_	11	prep	11:AM-TMP
16	their	their	PRP$	_	17	poss	_
17	effectiveness	effectiveness	NN	_	15	pobj	_
18	in	in	IN	_	17	prep	_
19	idiopathic	idiopathic	JJ	_	21	amod	_
20	pulmonary	pulmonary	JJ	_	21	amod	_
21	fibrosis	fibrosis	NN	_	18	pobj	_
22	(	(	-LRB-	_	23	punct	_
23	IPF	ipf	NNP	_	21	appos	_
24	)	)	-RRB-	_	23	punct	_
25	,	,	,	_	23	punct	_
26	a	a	DT	_	29	det	_
27	progressive	progressive	JJ	_	29	amod	_
28	scarring	scarring	NN	p2=JJ	29	nn	_
29	disease	disease	NN	_	23	appos	38:A0=PAG
30	of	of	IN	_	29	prep	_
31	the	the	DT	_	32	det	_
32	lungs	lung	NNS	_	30	pobj	34:A0=PAG
33	primarily	primarily	RB	_	34	advmod	34:AM-ADV
34	affecting	affect	VBG	pb=affect.01	32	partmod	_
35	the	the	DT	_	36	det	_
36	elderly	elderly	JJ	_	34	dobj	34:A1=PPT
37	that	that	WDT	p2=DT	38	nsubj	38:R-A0
38	has	have	VBZ	pb=have.03	29	rcmod	_
39	a	a	DT	_	44	det	_
40	3	0	CD	_	42	hmod	_
41	-	-	HYPH	_	42	hyph	_
42	year	year	NN	_	44	nn	_
43	survival	survival	NN	_	44	nn	_
44	rate	rate	NN	_	38	dobj	38:A1=PPT
45	of	of	IN	_	44	prep	_
46	about	about	RB	p2=IN	47	advmod	_
47	50	0	CD	_	48	num	_
48	percent	percent	NN	_	45	pobj	_
49	,	,	,	_	44	punct	_
50	a	a	DT	_	52	det	_
51	worse	bad	JJR	_	52	amod	_
52	prognosis	prognosis	NN	_	44	appos	_
53	than	than	IN	_	52	prep	_
54	that	that	DT	p2=IN	53	pobj	_
55	for	for	IN	_	52	prep	_
56	many	many	JJ	_	57	amod	_
57	cancers	cancer	NNS	_	55	pobj	_
58	.	.	.	_	11	punct	_

1	Two	#crd#	CD	_	6	nsubjpass	9:A0=PAG;6:A1=PPT
2	of	of	IN	_	1	prep	_
3	these	these	DT	_	4	det	_
4	drugs	drug	NNS	_	2	pobj	_
5	were	be	VBD	_	6	auxpass	_
6	found	find	VBN	pb=find.01	0	root	_
7	to	to	TO	_	9	aux	_
8	significantly	significantly	RB	_	9	advmod	9:AM-MNR
9	improve	improve	VB	pb=improve.01	6	xcomp	_
10	IPF	ipf	NNP	p2=IN	11	nn	_
11	patients	patient	NNS	_	13	poss	_
12	'	'	POS	_	11	possessive	_
13	symptoms	symptom	NNS	_	9	dobj	9:A1=PPT
14	,	,	,	_	6	punct	_
15	and	and	CC	_	6	cc	_
16	one	#crd#	CD	p2=NN	18	num	_
17	,	,	,	_	21	punct	_
18	pirfenidone	pirfenidone	NN	p2=UH	21	nsubjpass	23:A0;21:A1=PPT
19	,	,	,	_	18	punct	_
20	was	be	VBD	_	21	auxpass	_
21	shown	show	VBN	pb=show.01	6	conj	_
22	to	to	TO	_	23	aux	_
23	reduce	reduce	VB	pb=reduce.01	21	xcomp	21:C-A1
24	the	the	DT	_	25	det	_
25	risk	risk	NN	_	23	dobj	23:A1=PPT
26	of	of	IN	_	25	prep	_
27	death	death	NN	_	26	pobj	_
28	from	from	IN	_	23	prep	23:A3=DIR
29	IPF by	ipf by	NNP	p2=PRP$	28	pobj	_
30	68	0	CD	_	31	num	_
31	percent	percent	NN	_	23	dobj	_
32	in	in	IN	_	31	prep	_
33	a	a	DT	_	35	det	_
34	combined	combined	JJ	p2=VBN	35	amod	_
35	group	group	NN	_	32	pobj	_
36	of	of	IN	_	35	prep	_
37	patients	patient	NNS	_	36	pobj	39:A0=PAG
38	who	who	WP	_	39	nsubj	39:R-A0
39	received	receive	VBD	pb=receive.01	37	rcmod	_
40	the	the	DT	_	41	det	_
41	drug	drug	NN	_	39	dobj	39:A1=PPT
42	during	during	IN	_	39	prep	39:AM-TMP
43	the	the	DT	_	47	det	_
44	year	year	NN	_	46	hmod	_
45	-	-	HYPH	_	46	hyph	_
46	long	long	JJ	_	47	amod	_
47	trial	trial	NN	_	42	pobj	_
48	.	.	.	_	21	punct	_

1	Two	#crd#	CD	_	3	num	_
2	additional	additional	JJ	_	3	amod	_
3	trials	trial	NNS	_	4	nsubj	4:A0=PAG
4	assessed	assess	VBD	pb=assess.01	0	root	_
5	the	the	DT	_	6	det	_
6	effectiveness	effectiveness	NN	_	4	dobj	4:A1=PPT
7	of	of	IN	_	6	prep	_
8	statin	statin	JJ	p2=NN	9	amod	_
9	drugs	drug	NNS	_	7	pobj	_
10	in	in	IN	_	4	prep	4:AM-LOC
11	acute	acute	JJ	_	14	amod	_
12	respiratory	respiratory	JJ	_	14	amod	_
13	distress	distress	NN	_	14	nn	_
14	syndrome	syndrome	NN	_	10	pobj	_
15	(	(	-LRB-	_	16	punct	_
16	ARDS	ards	NNP	p2=NNS	14	appos	_
17	)	)	-RRB-	_	16	punct	_
18	and	and	CC	_	14	cc	_
19	chronic	chronic	JJ	_	22	amod	_
20	pulmonary	pulmonary	JJ	_	22	amod	_
21	obstructive	obstructive	JJ	p2=NN	22	amod	_
22	disease	disease	NN	_	14	conj	_
23	(	(	-LRB-	_	22	punct	_
24	COPD	copd	NNP	p2=NN	22	appos	_
25	)	)	-RRB-	_	22	punct	_
26	.	.	.	_	4	punct	_

1	Neither	neither	DT	p2=CC	2	det	_
2	statin	statin	NN	_	4	nsubjpass	4:A1=PPT
3	was	be	VBD	_	4	auxpass	_
4	found	find	VBN	pb=find.01	0	root	_
5	to	to	TO	_	6	aux	_
6	provide	provide	VB	pb=provide.01	4	advcl	_
7	benefit	benefit	NN	_	6	dobj	6:A1=PPT
8	for	for	IN	_	7	prep	_
9	patients	patient	NNS	_	8	pobj	_
10	with	with	IN	_	9	prep	_
11	these	these	DT	_	12	det	_
12	conditions	condition	NNS	_	10	pobj	_
13	.	.	.	_	4	punct	_

1	The	the	DT	_	2	det	_
2	findings	finding	NNS	_	9	nsubjpass	9:A1
3	of	of	IN	_	2	prep	_
4	all	all	DT	_	6	det	_
5	five	#crd#	CD	_	6	num	_
6	studies	study	NNS	_	3	pobj	_
7	are	be	VBP	_	9	aux	_
8	being	be	VBG	_	9	auxpass	_
9	reported	report	VBN	pb=report.01	0	root	_
10	at	at	IN	_	9	prep	9:AM-LOC
11	the	the	DT	_	13	det	_
12	annual	annual	JJ	_	13	amod	_
13	meeting	meeting	NN	_	10	pobj	_
14	of	of	IN	_	13	prep	_
15	the	the	DT	_	18	det	_
16	American	american	NNP	p2=JJ	18	nn	_
17	Thoracic	thoracic	NNP	_	18	nn	_
18	Society	society	NNP	_	14	pobj	_
19	,	,	,	_	21	punct	_
20	being	be	VBG	_	21	auxpass	_
21	held	hold	VBN	pb=hold.04	2	partmod	_
22	this	this	DT	_	23	det	_
23	year	year	NN	_	21	npadvmod	21:AM-TMP
24	in	in	IN	_	21	prep	21:AM-LOC
25	San	san	NNP	_	26	nn	_
26	Diego	diego	NNP	_	24	pobj	_
27	,	,	,	_	26	punct	_
28	Calif	calif	NNP	_	26	appos	_
29	.	.	.	_	9	punct	_

1	,	,	,	_	7	punct	_
2	from	from	IN	_	0	root	_
3	May	may	NNP	_	2	pobj	_
4	16	0	CD	_	3	num	_
5	to	to	IN	_	2	prep	_
6	May	may	NNP	_	5	pobj	_
7	21	0	CD	_	6	num	_
8	.	.	.	_	2	punct	_

1	The	the	DT	_	3	det	_
2	pirfenidone	pirfenidone	NN	p2=JJ	3	nn	_
3	trial	trial	NN	_	5	nsubjpass	5:A1=PPT
4	was	be	VBD	_	5	auxpass	_
5	led	lead	VBN	pb=lead.02	0	root	_
6	by	by	IN	_	5	agent	5:A0=PAG
7	Talmadge	talmadge	NNP	_	9	nn	_
8	E.	e.	NNP	_	9	nn	_
9	King	king	NNP	_	6	pobj	_
10	,	,	,	_	9	punct	_
11	Jr	jr	NNP	_	9	appos	_
12	.	.	.	_	5	punct	_

1	,	,	,	_	2	punct	_
2	MD	md	NNP	_	23	nsubj	_
3	,	,	,	_	2	punct	_
4	professor	professor	NN	_	2	appos	_
5	and	and	CC	_	4	cc	_
6	chair	chair	NN	_	4	conj	_
7	of	of	IN	_	6	prep	_
8	UCSF	ucsf	NNP	_	10	poss	_
9	's	's	POS	_	8	possessive	_
10	Department	department	NNP	_	7	pobj	_
11	of	of	IN	_	10	prep	_
12	Medicine	medicine	NNP	_	11	pobj	_
13	,	,	,	_	2	punct	_
14	in	in	IN	_	0	root	_
15	his	his	PRP$	_	16	poss	_
16	role	role	NN	_	14	pobj	_
17	as	as	IN	_	16	prep	_
18	member	member	NN	_	17	pobj	_
19	of	of	IN	_	18	prep	_
20	a	a	DT	_	22	det	_
21	research	research	NN	_	22	nn	_
22	consortium	consortium	NN	_	19	pobj	23:A1=PPT
23	known	know	VBN	pb=know.01	22	partmod	_
24	as	as	IN	_	23	prep	23:A2=PRD
25	the	the	DT	_	28	det	_
26	ASCEND	ascend	NNP	_	28	nn	_
27	Study	study	NNP	_	28	nn	_
28	Group	group	NNP	_	24	pobj	_
29	.	.	.	_	2	punct	_

1	Though	though	IN	_	3	mark	_
2	this	this	DT	_	3	det	_
3	drug	drug	NN	_	0	root	5:A1=PRD
4	,	,	,	_	3	punct	_
5	manufactured	manufacture	VBN	pb=manufacture.01	3	partmod	_
6	by	by	IN	_	5	agent	5:A0=PAG
7	Brisbane	brisbane	NNP	_	6	pobj	_
8	,	,	,	_	7	punct	_
9	Calif	calif	NNP	_	7	appos	_
10	.	.	.	_	3	punct	_

1	-	-	HYPH	p2=:	2	hyph	_
2	based	base	VBN	_	3	amod	_
3	InterMune	intermune	NNP	p2=NN	7	nsubjpass	7:A1=PPT
4	,	,	,	_	18	punct	_
5	has	have	VBZ	_	7	aux	_
6	been	be	VBN	_	7	auxpass	_
7	approved	approve	VBN	pb=approve.01	18	ccomp	_
8	for	for	IN	_	7	prep	7:A2=PRD
9	IPF	ipf	NNP	p2=NN	8	pobj	_
10	in	in	IN	_	9	prep	_
11	other	other	JJ	_	12	amod	_
12	countries	country	NNS	_	10	pobj	_
13	,	,	,	_	18	punct	_
14	it	it	PRP	_	18	nsubj	18:A0=PAG
15	has	have	VBZ	_	18	aux	_
16	not	not	RB	_	18	neg	18:AM-NEG
17	yet	yet	RB	_	18	advmod	18:AM-TMP
18	received	receive	VBN	pb=receive.01	0	root	_
19	approval	approval	NN	_	18	dobj	18:A1=PPT
20	from	from	IN	_	19	prep	_
21	the	the	DT	_	26	det	_
22	U.S.	u.s.	NNP	_	26	nn	_
23	Food	food	NNP	_	26	nn	_
24	and	and	CC	_	23	cc	_
25	Drug	drug	NNP	_	23	conj	_
26	Administration	administration	NNP	_	20	pobj	_
27	(	(	-LRB-	_	28	punct	_
28	FDA	fda	NNP	_	26	appos	_
29	)	)	-RRB-	_	28	punct	_
30	.	.	.	_	18	punct	_

1	Harold	harold	NNP	_	3	nn	_
2	R.	r.	NNP	_	3	nn	_
3	Collard	collard	NNP	_	21	nsubj	21:A1=PPT
4	,	,	,	_	3	punct	_
5	MD	md	NNP	_	3	appos	_
6	,	,	,	_	5	punct	_
7	associate	associate	JJ	p2=NN	8	amod	_
8	professor	professor	NN	_	5	appos	_
9	of	of	IN	_	8	prep	_
10	medicine	medicine	NN	_	9	pobj	_
11	and	and	CC	_	10	cc	_
12	director	director	NN	_	10	conj	_
13	of	of	IN	_	10	prep	_
14	UCSF	ucsf	NNP	_	19	poss	_
15	's	's	POS	_	14	possessive	_
16	Interstitial	interstitial	NNP	_	19	nn	_
17	Lung	lung	NNP	_	19	nn	_
18	Disease	disease	NNP	_	19	nn	_
19	Program	program	NNP	_	13	pobj	_
20	,	,	,	_	21	punct	_
21	was	be	VBD	pb=be.01	0	root	_
22	a	a	DT	_	23	det	_
23	member	member	NN	_	21	attr	21:A2=PRD
24	of	of	IN	_	23	prep	_
25	the	the	DT	_	28	det	_
26	INPULSIS	inpulsis	NNP	_	28	nn	_
27	Trial	trial	NNP	_	28	nn	_
28	Investigators	investigator	NNPS	p2=NNP	24	pobj	_
29	,	,	,	_	28	punct	_
30	a	a	DT	_	32	det	_
31	research	research	NN	_	32	nn	_
32	group	group	NN	_	28	appos	34:A0=PAG
33	that	that	WDT	_	34	nsubj	34:R-A0
34	tested	test	VBD	pb=test.01	32	rcmod	_
35	the	the	DT	_	36	det	_
36	effectiveness	effectiveness	NN	_	34	dobj	34:A1=LOC
37	in	in	IN	_	34	prep	34:AM-LOC
38	IPF	ipf	NNP	_	37	pobj	_
39	of	of	IN	_	38	prep	_
40	nintedanib	nintedanib	NNP	p2=CD	39	pobj	_
41	,	,	,	_	40	punct	_
42	a	a	DT	_	43	det	_
43	drug	drug	NN	_	40	appos	45:A1=PPT
44	that	that	WDT	_	45	nsubj	45:R-A0
45	tamps	tamp	VBZ	pb=tamp.01	43	rcmod	_
46	down	down	RP	p2=IN	45	prep	45:A2=MNR
47	the	the	DT	_	48	det	_
48	formation	formation	NN	_	46	pobj	_
49	of	of	IN	_	48	prep	_
50	new	new	JJ	_	52	amod	_
51	blood	blood	NN	_	52	nn	_
52	vessels	vessel	NNS	_	49	pobj	_
53	.	.	.	_	21	punct	_

1	This	this	DT	_	2	det	_
2	trial	trial	NN	_	4	nsubj	4:A0=PAG
3	also	also	RB	_	4	advmod	4:AM-DIS
4	reported	report	VBD	pb=report.01	0	root	_
5	a	a	DT	_	7	det	_
6	significant	significant	JJ	_	7	amod	_
7	improvement	improvement	NN	_	4	dobj	4:A1
8	in	in	IN	_	7	prep	_
9	symptoms	symptom	NNS	_	8	pobj	_
10	in	in	IN	_	9	prep	_
11	patients	patient	NNS	_	10	pobj	12:A0=PAG
12	receiving	receive	VBG	pb=receive.01	11	partmod	_
13	the	the	DT	_	14	det	_
14	drug	drug	NN	_	12	dobj	12:A1=PPT
15	.	.	.	_	4	punct	_

1	King	king	NNP	_	3	nsubj	3:A0
2	also	also	RB	_	3	advmod	3:AM-DIS
3	took	take	VBD	pb=take.01	0	root	_
4	part	part	NN	_	3	dobj	3:A1=PPT
5	in	in	IN	_	3	prep	3:AM-LOC
6	a	a	DT	_	7	det	_
7	study	study	NN	_	5	pobj	_
8	of	of	IN	_	7	prep	_
9	a	a	DT	_	10	det	_
10	compound	compound	NN	_	8	pobj	11:A1=PPT
11	known	know	VBN	pb=know.01	10	partmod	_
12	as	as	IN	_	11	prep	11:A2=PRD
13	acetylcysteine	acetylcysteine	NN	p2=JJ	12	pobj	15:A1=PPT
14	,	,	,	_	13	punct	_
15	conducted	conduct	VBN	pb=conduct.01	13	partmod	_
16	by	by	IN	_	15	agent	15:A0=PAG
17	the	the	DT	_	23	det	_
18	Idiopathic	idiopathic	NNP	p2=JJ	23	nn	_
19	Pulmonary	pulmonary	NNP	_	23	nn	_
20	Fibrosis	fibrosis	NNP	p2=NNPS	23	nn	_
21	Clinical	clinical	NNP	_	23	nn	_
22	Research	research	NNP	_	23	nn	_
23	Network	network	NNP	_	16	pobj	_
24	.	.	.	_	3	punct	_

1	That	that	DT	p2=IN	2	det	_
2	trial	trial	NN	_	3	nsubj	3:A0=CAU
3	showed	show	VBD	pb=show.01	0	root	_
4	no	no	DT	_	6	det	_
5	significant	significant	JJ	_	6	amod	_
6	improvement	improvement	NN	_	3	dobj	3:A1=PPT
7	in	in	IN	_	6	prep	_
8	symptoms	symptom	NNS	_	7	pobj	_
9	among	among	IN	_	6	prep	_
10	patients	patient	NNS	_	9	pobj	11:A0
11	taking	take	VBG	pb=take.01	10	partmod	_
12	the	the	DT	_	13	det	_
13	drug	drug	NN	_	11	dobj	11:A1=PPT
14	.	.	.	_	3	punct	_

1	There	there	EX	_	3	expl	_
2	have	have	VBP	_	3	aux	_
3	been	be	VBN	pb=be.02	0	root	_
4	virtually	virtually	RB	_	5	advmod	_
5	no	no	DT	p2=IN	7	num	_
6	effective	effective	JJ	_	7	amod	_
7	treatments	treatment	NNS	_	3	attr	3:A1=PPT
8	for	for	IN	_	7	prep	_
9	IPF	ipf	NNP	p2=NN	8	pobj	_
10	,	,	,	_	3	punct	_
11	and	and	CC	_	3	cc	_
12	the	the	DT	_	16	det	_
13	pirfenidone	pirfenidone	NN	p2=JJ	16	nn	_
14	and	and	CC	_	13	cc	_
15	nintedanib	nintedanib	NN	p2=JJ	13	conj	_
16	trials	trial	NNS	_	18	nsubjpass	18:A1=PPT
17	were	be	VBD	_	18	auxpass	_
18	hailed	hail	VBN	pb=hail.02	3	conj	_
19	in	in	IN	_	18	prep	18:AM-LOC
20	an	an	DT	_	23	det	_
21	accompanying	accompany	VBG	p2=JJ|pb=accompany.01	23	amod	_
22	NEJM	nejm	NNP	p2=NN	23	nn	_
23	editorial	editorial	NN	p2=JJ	19	pobj	21:A0=PAG
24	as	as	IN	_	23	prep	_
25	"	"	``	_	24	punct	_
26	a	a	DT	_	28	det	_
27	major	major	JJ	_	28	amod	_
28	breakthrough	breakthrough	NN	_	24	pobj	_
29	for	for	IN	_	28	prep	_
30	patients	patient	NNS	_	29	pobj	_
31	,	,	,	_	18	punct	_
32	"	"	''	p2=``	18	punct	_
33	though	though	IN	_	35	mark	_
34	it	it	PRP	_	35	nsubj	35:A1=PPT;38:A1
35	remains	remain	VBZ	pb=remain.01	18	advcl	18:AM-ADV
36	to	to	TO	_	38	aux	_
37	be	be	VB	_	38	auxpass	_
38	seen	see	VBN	pb=see.01	35	xcomp	35:A3=PRD
39	how	how	WRB	p2=RB	40	advmod	_
40	well	well	RB	p2=PDT	44	advmod	44:R-AM-MNR
41	these	these	DT	_	42	det	_
42	drugs	drug	NNS	_	44	nsubj	44:A0=PAG
43	will	will	MD	_	44	aux	44:AM-MOD
44	work	work	VB	pb=work.01	38	ccomp	_
45	in	in	IN	_	44	prep	44:AM-LOC
46	patients	patient	NNS	_	45	pobj	48:A1=PPT
47	who	who	WP	_	48	nsubj	48:R-A1
48	are	be	VBP	pb=be.01	46	rcmod	_
49	more	more	RBR	_	50	advmod	_
50	severely	severely	RB	_	51	advmod	_
51	ill	ill	JJ	_	48	acomp	48:A2=PRD
52	than	than	IN	_	51	prep	_
53	those	those	DT	_	52	pobj	55:A1=PPT
54	who	who	WP	_	55	nsubj	55:R-A1
55	qualified	qualify	VBD	p2=VBP|pb=qualify.02	53	rcmod	_
56	for	for	IN	_	55	prep	55:A2=PRD
57	the	the	DT	_	58	det	_
58	trials	trial	NNS	_	56	pobj	_
59	.	.	.	_	18	punct	_

1	But	but	CC	_	48	cc	48:AM-DIS
2	the	the	DT	_	3	det	_
3	success	success	NN	_	21	nsubj	21:A0=PAG
4	of	of	IN	_	3	prep	_
5	pirfenidone	pirfenidone	NN	_	4	pobj	_
6	and	and	CC	_	5	cc	_
7	nintedanib	nintedanib	NN	p2=NNS	5	conj	_
8	,	,	,	_	3	punct	_
9	and	and	CC	_	3	cc	_
10	the	the	DT	_	11	det	_
11	failure	failure	NN	_	3	conj	_
12	of	of	IN	_	11	prep	_
13	acetylcysteine	acetylcysteine	NN	p2=NNP	12	pobj	16:A0=PAG
14	,	,	,	_	13	punct	_
15	which	which	WDT	_	16	nsubj	16:R-A0
16	targets	target	VBZ	pb=target.01	13	rcmod	_
17	inflammatory	inflammatory	JJ	_	18	amod	_
18	responses	response	NNS	_	16	dobj	16:A1=PPT
19	,	,	,	_	48	punct	_
20	"	"	''	p2=``	21	punct	_
21	mean	mean	VBP	p2=VB|pb=mean.01	48	ccomp	_
22	that	that	IN	_	24	complm	_
23	it	it	PRP	_	24	nsubj	24:A1=PPT
24	is	be	VBZ	pb=be.01	21	ccomp	21:A1=PPT
25	now	now	RB	_	24	advmod	24:AM-TMP
26	clear	clear	JJ	_	24	acomp	24:A2=PRD
27	that	that	IN	p2=WDT	31	complm	_
28	idiopathic	idiopathic	JJ	_	30	amod	_
29	pulmonary	pulmonary	JJ	_	30	amod	_
30	fibrosis	fibrosis	NN	_	31	nsubj	31:A1=PPT
31	is	be	VBZ	pb=be.01	24	ccomp	_
32	a	a	DT	_	33	det	_
33	disease	disease	NN	_	31	attr	34:A1=PPT;31:A2=PRD
34	perpetuated	perpetuate	VBN	pb=perpetuate.01	33	partmod	_
35	by	by	IN	_	34	agent	34:A0=PAG
36	aberrant	aberrant	JJ	p2=NN	38	amod	_
37	wound	wound	NN	p2=JJ	38	nn	_
38	healing	healing	NN	_	35	pobj	_
39	,	,	,	_	38	punct	_
40	rather	rather	RB	_	41	advmod	_
41	than	than	IN	_	38	cc	_
42	primarily	primarily	RB	_	43	advmod	_
43	by	by	IN	_	41	prep	_
44	chronic	chronic	JJ	_	45	amod	_
45	inflammation	inflammation	NN	_	43	pobj	_
46	,	,	,	_	48	punct	_
47	"	"	''	p2=``	48	punct	_
48	writes	write	VBZ	pb=write.01	0	root	_
49	editorial	editorial	NN	p2=JJ	50	amod	_
50	author	author	NN	_	53	nn	_
51	Gary	gary	NNP	_	53	nn	_
52	M.	m.	NNP	_	53	nn	_
53	Hunninghake	hunninghake	NNP	_	48	nsubj	48:A0=PAG
54	,	,	,	_	53	punct	_
55	MD	md	NNP	_	53	appos	_
56	,	,	,	_	55	punct	_
57	MPH	mph	NNP	_	55	appos	_
58	,	,	,	_	55	punct	_
59	of	of	IN	_	55	prep	_
60	Brigham	brigham	NNP	p2=NN	59	pobj	_
61	and	and	CC	_	55	cc	_
62	Women	women	NNP	p2=NNPS	64	poss	_
63	's	's	POS	_	62	possessive	_
64	Hospital	hospital	NNP	_	55	conj	_
65	in	in	IN	_	64	prep	_
66	Boston	boston	NNP	_	65	pobj	_
67	,	,	,	_	53	punct	_
68	and	and	CC	_	53	cc	_
69	this	this	DT	_	71	det	_
70	new	new	JJ	_	71	amod	_
71	knowledge	knowledge	NN	_	53	conj	_
72	should	should	MD	_	73	aux	73:AM-MOD
73	lead	lead	VB	pb=lead.03	48	ccomp	48:A1=PPT
74	to	to	IN	_	73	prep	73:A2=PRD
75	more	more	JJR	p2=RBR	77	amod	_
76	new	new	JJ	_	77	amod	_
77	treatments	treatment	NNS	_	74	pobj	_
78	.	.	.	_	48	punct	_

1	In	in	IN	_	40	prep	40:AM-LOC
2	a	a	DT	_	4	det	_
3	fourth	#ord#	JJ	_	4	amod	_
4	trial	trial	NN	_	1	pobj	5:A1=PRD
5	published	publish	VBN	pb=publish.01	4	partmod	_
6	in	in	IN	_	5	prep	5:AM-LOC
7	this	this	DT	_	8	det	_
8	week	week	NN	_	10	poss	_
9	's	's	POS	_	8	possessive	_
10	NEJM	nejm	NNP	p2=NN	6	pobj	_
11	,	,	,	_	10	punct	_
12	UCSF	ucsf	NNP	_	16	poss	_
13	's	's	POS	_	12	possessive	_
14	Michael	michael	NNP	_	16	nn	_
15	A.	a.	NNP	_	16	nn	_
16	Matthay	matthay	NNP	_	10	conj	_
17	,	,	,	_	16	punct	_
18	MD	md	NNP	_	16	appos	_
19	,	,	,	_	18	punct	_
20	professor	professor	NN	_	16	appos	_
21	of	of	IN	_	20	prep	_
22	medicine	medicine	NN	_	21	pobj	_
23	and	and	CC	_	22	cc	_
24	anesthesia	anesthesia	NN	p2=NNS	22	conj	_
25	,	,	,	_	16	punct	_
26	and	and	CC	_	16	cc	_
27	Kathleen	kathleen	NNP	_	29	nn	_
28	D.	d.	NNP	_	29	nn	_
29	Liu	liu	NNP	_	16	conj	_
30	,	,	,	_	29	punct	_
31	MD	md	NNP	_	29	appos	_
32	,	,	,	_	31	punct	_
33	PhD	phd	NN	p2=NNP	31	conj	_
34	,	,	,	_	33	punct	_
35	associate	associate	JJ	p2=NN	36	amod	_
36	professor	professor	NN	_	33	conj	_
37	of	of	IN	_	36	prep	_
38	medicine	medicine	NN	_	37	pobj	_
39	,	,	,	_	36	punct	_
40	took	take	VBD	pb=take.01	0	root	_
41	part	part	NN	_	40	dobj	40:A1=PPT
42	in	in	IN	_	40	prep	40:AM-LOC
43	a	a	DT	_	44	det	_
44	study	study	NN	_	42	pobj	_
45	of	of	IN	_	44	prep	_
46	the	the	DT	_	47	det	_
47	effectiveness	effectiveness	NN	_	45	pobj	_
48	of	of	IN	_	47	prep	_
49	rosuvastatin	rosuvastatin	NN	p2=NNP	48	pobj	_
50	(	(	-LRB-	_	53	punct	_
51	trade	trade	NN	_	52	nn	_
52	name	name	NN	_	53	nn	_
53	Crestor	crestor	NNP	p2=NN	47	appos	_
54	)	)	-RRB-	_	53	punct	_
55	in	in	IN	_	44	prep	_
56	ARDS	ards	NNP	p2=NNS	55	pobj	_
57	.	.	.	_	40	punct	_

1	The	the	DT	_	2	det	_
2	trial	trial	NN	_	20	nsubj	22:A0=PAG;4:A1=PPT;20:A1=PAG
3	,	,	,	_	2	punct	_
4	conducted	conduct	VBN	pb=conduct.01	2	partmod	_
5	by	by	IN	_	4	agent	4:A0=PAG
6	The	the	DT	p2=NNP	8	det	_
7	National	national	NNP	_	8	nn	_
8	Heart	heart	NNP	p2=NN	5	pobj	_
9	,	,	,	_	8	punct	_
10	Lung	lung	NNP	_	8	conj	_
11	,	,	,	_	2	punct	_
12	and	and	CC	_	2	cc	_
13	Blood	blood	NN	p2=NNP	2	conj	_
14	Institute	institute	NNP	_	18	nn	_
15	ARDS	ards	NNP	p2=NNPS	18	nn	_
16	Clinical	clinical	NNP	p2=JJ	18	nn	_
17	Trials	trials	NNP	p2=NNPS	18	nn	_
18	Network	network	NNP	_	2	appos	_
19	,	,	,	_	2	punct	_
20	failed	fail	VBD	pb=fail.01	0	root	_
21	to	to	TO	_	22	aux	_
22	find	find	VB	pb=find.01	20	xcomp	20:A2=PPT
23	any	any	DT	_	24	det	_
24	benefit	benefit	NN	_	22	dobj	22:A1=PPT
25	from	from	IN	_	24	prep	_
26	this	this	DT	_	27	det	_
27	treatment	treatment	NN	_	25	pobj	_
28	.	.	.	_	20	punct	_

1	Finally	finally	RB	_	56	advmod	56:AM-TMP
2	,	,	,	_	56	punct	_
3	in	in	IN	_	56	prep	56:AM-LOC
4	a	a	DT	_	5	det	_
5	study	study	NN	_	3	pobj	_
6	of	of	IN	_	5	prep	_
7	the	the	DT	_	8	det	_
8	effectiveness	effectiveness	NN	_	6	pobj	_
9	of	of	IN	_	8	prep	_
10	simvastatin	simvastatin	NN	p2=JJ	9	pobj	_
11	(	(	-LRB-	_	14	punct	_
12	trade	trade	NN	_	13	nn	_
13	name	name	NN	_	14	nn	_
14	Zocor	zocor	NNP	_	8	appos	_
15	)	)	-RRB-	_	14	punct	_
16	in	in	IN	_	8	prep	_
17	COPD	copd	NNP	_	16	pobj	_
18	,	,	,	_	17	punct	_
19	Steven	steven	NNP	_	21	nn	_
20	C.	c.	NNP	_	21	nn	_
21	Lazarus	lazarus	NNP	_	17	conj	_
22	,	,	,	_	21	punct	_
23	MD	md	NNP	_	21	appos	_
24	,	,	,	_	21	punct	_
25	professor	professor	NN	_	21	appos	_
26	of	of	IN	_	25	prep	_
27	medicine	medicine	NN	_	26	pobj	_
28	,	,	,	_	56	punct	_
29	Prescott	prescott	NNP	_	31	nn	_
30	G.	g.	NNP	_	31	nn	_
31	Woodruff	woodruff	NNP	_	56	nsubj	56:A0
32	,	,	,	_	31	punct	_
33	MD	md	NNP	_	31	appos	_
34	,	,	,	_	33	punct	_
35	associate	associate	JJ	p2=NN	36	amod	_
36	professor	professor	NN	_	33	appos	_
37	of	of	IN	_	36	prep	_
38	medicine	medicine	NN	_	37	pobj	_
39	,	,	,	_	31	punct	_
40	and	and	CC	_	31	cc	_
41	members	member	NNS	p2=VBZ	31	conj	_
42	the	the	DT	_	46	det	_
43	COPD	copd	NNP	_	46	nn	_
44	Clinical	clinical	NNP	_	46	nn	_
45	Research	research	NNP	_	46	nn	_
46	Network	network	NNP	_	41	appos	_
47	and	and	CC	_	46	cc	_
48	the	the	DT	_	50	det	_
49	Canadian	canadian	NNP	p2=JJ	50	nn	_
50	Institutes	institute	NNPS	_	46	conj	_
51	of	of	IN	_	50	prep	_
52	Health	health	NNP	_	53	nn	_
53	Research	research	NNP	_	51	pobj	_
54	did	do	VBD	_	56	aux	_
55	not	not	RB	_	56	neg	56:AM-NEG
56	establish	establish	VB	pb=establish.01	0	root	_
57	any	any	DT	_	59	det	_
58	clinical	clinical	JJ	_	59	amod	_
59	benefit	benefit	NN	_	56	dobj	56:A1=PPT
60	for	for	IN	_	59	prep	_
61	the	the	DT	_	62	det	_
62	drug	drug	NN	_	60	pobj	_
63	.	.	.	_	56	punct	_

1	Though	though	IN	_	8	mark	_
2	the	the	DT	_	3	det	_
3	findings	finding	NNS	_	8	nsubj	8:A1=PPT
4	of	of	IN	_	3	prep	_
5	both	both	DT	p2=CC	7	det	_
6	statin	statin	JJ	p2=NN	7	amod	_
7	trials	trial	NNS	_	4	pobj	_
8	were	be	VBD	pb=be.01	13	advcl	13:AM-ADV
9	negative	negative	JJ	_	8	acomp	8:A2=PRD
10	,	,	,	_	13	punct	_
11	these	these	DT	_	12	det	_
12	results	result	NNS	_	13	nsubj	13:A1=PPT
13	are	be	VBP	pb=be.01	16	ccomp	16:A1=PPT
14	important	important	JJ	_	13	acomp	13:A2=PRD
15	,	,	,	_	16	punct	_
16	said	say	VBD	pb=say.01	0	root	_
17	an	an	DT	_	19	det	_
18	NEJM	nejm	NNP	p2=NN	19	nn	_
19	editorial	editorial	NN	_	16	nsubj	16:A0;20:A1=PPT
20	entitled	entitle	VBN	pb=entitle.02	19	partmod	_
21	"	"	``	p2=''	23	punct	_
22	Statin	statin	NNP	p2=JJ	23	nn	_
23	Strikeout	strikeout	NNP	_	20	oprd	20:A2=PRD
24	.	.	.	_	16	punct	_
25	"	"	''	_	16	punct	_

1	Both	both	DT	_	2	det	_
2	drugs	drug	NNS	_	21	nsubjpass	12:A0;7:A1=PPT;21:A1=PPT
3	,	,	,	_	2	punct	_
4	which	which	WDT	_	7	nsubjpass	12:R-A0;7:R-A1
5	have	have	VBP	_	7	aux	_
6	been	be	VBN	_	7	auxpass	_
7	approved	approve	VBN	pb=approve.01	2	rcmod	_
8	by	by	IN	_	7	agent	7:A0
9	the	the	DT	_	10	det	_
10	FDA	fda	NNP	_	8	pobj	_
11	to	to	TO	_	12	aux	_
12	reduce	reduce	VB	pb=reduce.01	7	xcomp	7:A2=PRD
13	inflammatory	inflammatory	JJ	_	14	amod	_
14	responses	response	NNS	_	12	dobj	12:A1=PPT
15	in	in	IN	_	14	prep	_
16	other	other	JJ	_	17	amod	_
17	conditions	condition	NNS	_	15	pobj	_
18	,	,	,	_	21	punct	_
19	have	have	VBP	_	21	aux	_
20	been	be	VBN	_	21	auxpass	_
21	given	give	VBN	pb=give.01	0	root	_
22	to	to	IN	_	21	prep	21:A2=GOL
23	patients	patient	NNS	_	22	pobj	_
24	on	on	IN	_	23	prep	_
25	the	the	DT	_	26	det	_
26	theory	theory	NN	_	24	pobj	_
27	that	that	IN	p2=WDT	30	complm	_
28	inflammatory	inflammatory	JJ	_	29	amod	_
29	mechanisms	mechanism	NNS	_	30	nsubj	30:A0=PPT
30	underlie	underlie	VBP	p2=VBD|pb=underlie.01	26	ccomp	_
31	both	both	DT	p2=CC	32	preconj	_
32	ARDS	ards	NNP	p2=NNS	30	dobj	30:A1=PPT
33	and	and	CC	_	32	cc	_
34	COPD	copd	NNP	_	32	conj	_
35	.	.	.	_	21	punct	_

1	Although	although	IN	_	12	mark	_
2	the	the	DT	_	3	det	_
3	theory	theory	NN	_	12	nsubj	12:A1=PPT
4	behind	behind	IN	_	3	prep	_
5	these	these	DT	_	11	det	_
6	"	"	``	_	9	punct	_
7	off	off	IN	p2=JJ	9	hmod	_
8	-	-	HYPH	_	9	hyph	_
9	label	label	NN	_	11	nn	_
10	"	"	''	p2=``	9	punct	_
11	uses	use	VBZ	p2=NNS	4	pobj	_
12	was	be	VBD	pb=be.01	0	root	_
13	reasonable	reasonable	JJ	_	12	acomp	12:A2=PRD
14	,	,	,	_	12	punct	_
15	and	and	CC	_	12	cc	_
16	clinical	clinical	JJ	_	17	amod	_
17	observations	observation	NNS	_	18	nsubj	20:A0=PAG;25:A0=PAG;18:A1=PPT
18	seemed	seem	VBD	pb=seem.01	12	conj	_
19	to	to	TO	_	20	aux	_
20	back	back	VB	pb=back.01	18	xcomp	18:C-A1
21	up	up	RP	_	20	prt	20:C-V
22	that	that	DT	_	23	det	_
23	theory	theory	NN	_	20	dobj	20:A1=PPT
24	,	,	,	_	20	punct	_
25	write	write	VB	p2=VBP|pb=write.01	20	conj	_
26	Jeffrey	jeffrey	NNP	_	28	nn	_
27	M.	m.	NNP	_	28	nn	_
28	Drazen	drazen	NNP	_	25	dobj	25:A1=PPT
29	,	,	,	_	28	punct	_
30	MD	md	NNP	_	28	appos	_
31	,	,	,	_	28	punct	_
32	and	and	CC	_	28	cc	_
33	Annetine	annetine	NNP	_	35	nn	_
34	C.	c.	NNP	_	35	nn	_
35	Gelijns	gelijns	NNP	p2=NNPS	28	conj	_
36	,	,	,	_	35	punct	_
37	PhD	phd	NNP	p2=NN	35	appos	_
38	,	,	,	_	35	punct	_
39	of	of	IN	_	28	prep	_
40	the	the	DT	_	42	det	_
41	Icahn	icahn	NNP	_	42	nn	_
42	School	school	NNP	_	39	pobj	_
43	of	of	IN	_	42	prep	_
44	Medicine	medicine	NNP	_	43	pobj	_
45	at	at	IN	_	25	prep	_
46	Mt	mt	NNP	_	45	pobj	_
47	.	.	.	_	18	punct	_

1	Sinai	sinai	NNP	p2=JJ	10	advcl	10:AM-TMP
2	in	in	IN	_	1	prep	_
3	New	new	NNP	_	4	nn	_
4	York	york	NNP	_	2	pobj	_
5	,	,	,	_	10	punct	_
6	double	double	JJ	_	8	hmod	_
7	-	-	HYPH	_	8	hyph	_
8	blind	blind	JJ	_	9	amod	_
9	trials	trial	NNS	_	10	nsubj	_
10	were	be	VBD	pb=be.01	0	root	_
11	essential	essential	JJ	_	10	acomp	10:A2=PRD
12	to	to	TO	_	13	aux	_
13	establish	establish	VB	pb=establish.01	10	xcomp	10:A1=PPT
14	whether	whether	IN	_	18	complm	_
15	these	these	DT	_	16	det	_
16	drugs	drug	NNS	_	18	nsubj	18:A1=PPT
17	really	really	RB	_	18	advmod	18:AM-ADV
18	are	be	VBP	pb=be.01	13	ccomp	13:A1=PPT
19	effective	effective	JJ	_	18	acomp	18:A2=PRD
20	in	in	IN	_	19	prep	_
21	these	these	DT	_	23	det	_
22	lung	lung	NN	p2=JJ	23	nn	_
23	diseases	disease	NNS	_	20	pobj	_
24	.	.	.	_	10	punct	_

